CED In Action: When CMS Will Pay For Amyvid
This article was originally published in RPM Report
Executive Summary
Here is CMS’ proposed coverage with evidence development policy for Lilly’s Amyvid.
You may also be interested in...
The “Value Of Knowing”
The following is an excerpt from CMS’ proposed decision memo denying coverage to Lily’s Amyvid for use as a diagnostic tool to rule-out Alzheimer’s.
The Value of Knowing: CMS Rejects Coverage of Lilly’s Amyvid – Except As Tool For Further Research
CMS is proposing to deny coverage of Lilly’s Alzheimer’s “rule-out” diagnostic Amyvid. The decision is important for biopharma manufacturers for several reasons, both as a demonstration that the agency really will refuse to pay for FDA approved drugs—and for how CMS thinks it can actually use its authority to encourage research on effective AD therapies.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.